TWI329647B - Vaccines - Google Patents

Vaccines Download PDF

Info

Publication number: TWI329647B
Authority: TW; Taiwan
Prior art keywords: sequence; gene; gag; nef; codon
Prior art date: 2001-12-11

Application number

TW091121625A

Other languages

English (en)

Chinese (zh)

Inventor

Beaton Andrew

Franz Ertl Peter

Wayne Gough Gerald

Lear Andrew

Philip Tite John

Ann Van Wely Catherine

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-11

Filing date

2002-09-20

Publication date

2010-09-01

2001-12-11 Priority claimed from GB0129604A external-priority patent/GB0129604D0/en

2002-03-19 Priority claimed from GB0206462A external-priority patent/GB0206462D0/en

2002-09-20 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2010-09-01 Application granted granted Critical

2010-09-01 Publication of TWI329647B publication Critical patent/TWI329647B/zh

Links

229960005486 vaccine Drugs 0.000 title description 15
239000002773 nucleotide Substances 0.000 claims abstract description 41
241000713772 Human immunodeficiency virus 1 Species 0.000 claims abstract description 17
101710177291 Gag polyprotein Proteins 0.000 claims abstract description 15
101710125418 Major capsid protein Proteins 0.000 claims abstract description 12
108090000623 proteins and genes Proteins 0.000 claims description 206
108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 70
108020004705 Codon Proteins 0.000 claims description 64
210000002706 plastid Anatomy 0.000 claims description 44
239000013598 vector Substances 0.000 claims description 44
102000004169 proteins and genes Human genes 0.000 claims description 41
125000003729 nucleotide group Chemical group 0.000 claims description 40
239000002671 adjuvant Substances 0.000 claims description 30
238000000034 method Methods 0.000 claims description 26
239000002253 acid Substances 0.000 claims description 25
230000014509 gene expression Effects 0.000 claims description 25
150000007523 nucleic acids Chemical group 0.000 claims description 22
239000003814 drug Substances 0.000 claims description 21
239000008194 pharmaceutical composition Substances 0.000 claims description 18
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 16
229910052737 gold Inorganic materials 0.000 claims description 16
239000010931 gold Substances 0.000 claims description 16
238000005457 optimization Methods 0.000 claims description 13
108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
230000000694 effects Effects 0.000 claims description 12
239000013603 viral vector Substances 0.000 claims description 10
238000002360 preparation method Methods 0.000 claims description 9
239000011324 bead Substances 0.000 claims description 7
201000010099 disease Diseases 0.000 claims description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
239000003085 diluting agent Substances 0.000 claims description 5
239000000546 pharmaceutical excipient Substances 0.000 claims description 5
101710145242 Minor capsid protein P3-RTD Proteins 0.000 claims description 4
238000007918 intramuscular administration Methods 0.000 claims description 4
230000008439 repair process Effects 0.000 claims description 3
238000006467 substitution reaction Methods 0.000 claims description 3
108700020134 Human immunodeficiency virus 1 nef Proteins 0.000 claims 2
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 2
241000282465 Canis Species 0.000 claims 1
101150102264 IE gene Proteins 0.000 claims 1
102100034343 Integrase Human genes 0.000 claims 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
239000004472 Lysine Substances 0.000 claims 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
208000026555 breast adenosis Diseases 0.000 claims 1
239000002574 poison Substances 0.000 claims 1
231100000614 poison Toxicity 0.000 claims 1
125000000430 tryptophan group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
108091033319 polynucleotide Proteins 0.000 abstract description 35
102000040430 polynucleotide Human genes 0.000 abstract description 35
239000012634 fragment Substances 0.000 abstract description 30
239000002157 polynucleotide Substances 0.000 abstract description 24
239000000427 antigen Substances 0.000 abstract description 17
108091007433 antigens Proteins 0.000 abstract description 17
102000036639 antigens Human genes 0.000 abstract description 17
241000725303 Human immunodeficiency virus Species 0.000 abstract description 15
102100034347 Integrase Human genes 0.000 description 71
239000000047 product Substances 0.000 description 55
210000004027 cell Anatomy 0.000 description 51
239000000203 mixture Substances 0.000 description 36
239000000499 gel Substances 0.000 description 33
108020004414 DNA Proteins 0.000 description 31
238000006243 chemical reaction Methods 0.000 description 30
238000009472 formulation Methods 0.000 description 25
150000001413 amino acids Chemical class 0.000 description 24
108090000765 processed proteins & peptides Proteins 0.000 description 24
108700010070 Codon Usage Proteins 0.000 description 21
102000039446 nucleic acids Human genes 0.000 description 16
108020004707 nucleic acids Proteins 0.000 description 16
239000002245 particle Substances 0.000 description 16
230000008488 polyadenylation Effects 0.000 description 16
230000002441 reversible effect Effects 0.000 description 16
241000701024 Human betaherpesvirus 5 Species 0.000 description 14
229940079593 drug Drugs 0.000 description 14
238000003780 insertion Methods 0.000 description 13
230000037431 insertion Effects 0.000 description 13
241000700605 Viruses Species 0.000 description 12
238000011144 upstream manufacturing Methods 0.000 description 12
241000283973 Oryctolagus cuniculus Species 0.000 description 11
230000004044 response Effects 0.000 description 11
230000004069 differentiation Effects 0.000 description 10
DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 10
102000004196 processed proteins & peptides Human genes 0.000 description 10
230000003612 virological effect Effects 0.000 description 10
102000004127 Cytokines Human genes 0.000 description 9
108090000695 Cytokines Proteins 0.000 description 9
229960002751 imiquimod Drugs 0.000 description 9
208000015181 infectious disease Diseases 0.000 description 9
210000004962 mammalian cell Anatomy 0.000 description 9
108700004028 nef Genes Proteins 0.000 description 9
101150023385 nef gene Proteins 0.000 description 9
239000000843 powder Substances 0.000 description 9
241000894007 species Species 0.000 description 9
239000004480 active ingredient Substances 0.000 description 8
239000008187 granular material Substances 0.000 description 8
239000007924 injection Substances 0.000 description 8
238000002347 injection Methods 0.000 description 8
230000035772 mutation Effects 0.000 description 8
239000000126 substance Substances 0.000 description 8
238000012546 transfer Methods 0.000 description 8
238000011282 treatment Methods 0.000 description 8
238000002255 vaccination Methods 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
108010076039 Polyproteins Proteins 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
230000000890 antigenic effect Effects 0.000 description 7
238000003556 assay Methods 0.000 description 7
108010006025 bovine growth hormone Proteins 0.000 description 7
230000004927 fusion Effects 0.000 description 7
230000002265 prevention Effects 0.000 description 7
230000002787 reinforcement Effects 0.000 description 7
238000012360 testing method Methods 0.000 description 7
210000002845 virion Anatomy 0.000 description 7
108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
108091026890 Coding region Proteins 0.000 description 6
102000003960 Ligases Human genes 0.000 description 6
108090000364 Ligases Proteins 0.000 description 6
125000003275 alpha amino acid group Chemical group 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
230000028993 immune response Effects 0.000 description 6
230000003053 immunization Effects 0.000 description 6
238000002649 immunization Methods 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
230000003993 interaction Effects 0.000 description 6
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
229920001184 polypeptide Polymers 0.000 description 6
239000000243 solution Substances 0.000 description 6
241000894006 Bacteria Species 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
101150104269 RT gene Proteins 0.000 description 5
101000865057 Thermococcus litoralis DNA polymerase Proteins 0.000 description 5
108020005202 Viral DNA Proteins 0.000 description 5
230000008859 change Effects 0.000 description 5
239000013604 expression vector Substances 0.000 description 5
108700004026 gag Genes Proteins 0.000 description 5
101150098622 gag gene Proteins 0.000 description 5
230000003308 immunostimulating effect Effects 0.000 description 5
230000010354 integration Effects 0.000 description 5
239000007788 liquid Substances 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
108700004029 pol Genes Proteins 0.000 description 5
101150088264 pol gene Proteins 0.000 description 5
238000000746 purification Methods 0.000 description 5
108091008146 restriction endonucleases Proteins 0.000 description 5
208000030507 AIDS Diseases 0.000 description 4
229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 4
108010041986 DNA Vaccines Proteins 0.000 description 4
229940021995 DNA vaccine Drugs 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
108091005804 Peptidases Proteins 0.000 description 4
206010036790 Productive cough Diseases 0.000 description 4
239000004365 Protease Substances 0.000 description 4
102000006382 Ribonucleases Human genes 0.000 description 4
108010083644 Ribonucleases Proteins 0.000 description 4
210000001744 T-lymphocyte Anatomy 0.000 description 4
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
238000002703 mutagenesis Methods 0.000 description 4
231100000350 mutagenesis Toxicity 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
230000010076 replication Effects 0.000 description 4
230000001177 retroviral effect Effects 0.000 description 4
239000007921 spray Substances 0.000 description 4
208000024794 sputum Diseases 0.000 description 4
239000003826 tablet Substances 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
238000011238 DNA vaccination Methods 0.000 description 3
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
208000031886 HIV Infections Diseases 0.000 description 3
208000037357 HIV infectious disease Diseases 0.000 description 3
241000238631 Hexapoda Species 0.000 description 3
108010002350 Interleukin-2 Proteins 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
108020004485 Nonsense Codon Proteins 0.000 description 3
101710192141 Protein Nef Proteins 0.000 description 3
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
-1 amine Schiff bases Chemical class 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
239000008280 blood Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000003197 catalytic effect Effects 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
239000002158 endotoxin Substances 0.000 description 3
238000001415 gene therapy Methods 0.000 description 3
239000000185 hemagglutinin Substances 0.000 description 3
210000005260 human cell Anatomy 0.000 description 3
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
229960001438 immunostimulant agent Drugs 0.000 description 3
239000003022 immunostimulating agent Substances 0.000 description 3
238000011081 inoculation Methods 0.000 description 3
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 3
229910052697 platinum Inorganic materials 0.000 description 3
239000002243 precursor Substances 0.000 description 3
230000002685 pulmonary effect Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
210000003491 skin Anatomy 0.000 description 3
210000003802 sputum Anatomy 0.000 description 3
238000010254 subcutaneous injection Methods 0.000 description 3
239000007929 subcutaneous injection Substances 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
230000014616 translation Effects 0.000 description 3
241000701161 unidentified adenovirus Species 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
FQYRLEXKXQRZDH-UHFFFAOYSA-N 4-aminoquinoline Chemical class C1=CC=C2C(N)=CC=NC2=C1 FQYRLEXKXQRZDH-UHFFFAOYSA-N 0.000 description 2
210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 2
108090000565 Capsid Proteins Proteins 0.000 description 2
102100023321 Ceruloplasmin Human genes 0.000 description 2
230000006820 DNA synthesis Effects 0.000 description 2
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
101710154606 Hemagglutinin Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
108010002352 Interleukin-1 Proteins 0.000 description 2
102000010638 Kinesin Human genes 0.000 description 2
108010063296 Kinesin Proteins 0.000 description 2
241000713666 Lentivirus Species 0.000 description 2
108010064171 Lysosome-Associated Membrane Glycoproteins Proteins 0.000 description 2
102000014944 Lysosome-Associated Membrane Glycoproteins Human genes 0.000 description 2
QXOHLNCNYLGICT-YFKPBYRVSA-N Met-Gly Chemical compound CSCC[C@H](N)C(=O)NCC(O)=O QXOHLNCNYLGICT-YFKPBYRVSA-N 0.000 description 2
101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 2
108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
101710176177 Protein A56 Proteins 0.000 description 2
101710149136 Protein Vpr Proteins 0.000 description 2
108700005077 Viral Genes Proteins 0.000 description 2
LTOCXIVQWDANEX-UXCYUTBZSA-M [Br-].CCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCCN)OCCCCCCCC\C=C/CCCC.CC(C)CCCC(C)CCCC(C)CCCC(C)CC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CC(C)CCCC(C)CCCC(C)CCCC(C)C Chemical compound [Br-].CCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCCN)OCCCCCCCC\C=C/CCCC.CC(C)CCCC(C)CCCC(C)CCCC(C)CC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CC(C)CCCC(C)CCCC(C)CCCC(C)C LTOCXIVQWDANEX-UXCYUTBZSA-M 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
230000003321 amplification Effects 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
239000011616 biotin Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
239000002775 capsule Substances 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
238000010367 cloning Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000010276 construction Methods 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
238000010828 elution Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
239000007789 gas Substances 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
239000000411 inducer Substances 0.000 description 2
239000007927 intramuscular injection Substances 0.000 description 2
239000007928 intraperitoneal injection Substances 0.000 description 2
239000003446 ligand Substances 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
239000002502 liposome Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
108010005942 methionylglycine Proteins 0.000 description 2
238000002156 mixing Methods 0.000 description 2
210000003928 nasal cavity Anatomy 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
229940023146 nucleic acid vaccine Drugs 0.000 description 2
239000002777 nucleoside Substances 0.000 description 2
150000003833 nucleoside derivatives Chemical class 0.000 description 2
239000003921 oil Substances 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
238000002161 passivation Methods 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
108010089520 pol Gene Products Proteins 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
230000000770 proinflammatory effect Effects 0.000 description 2
238000010839 reverse transcription Methods 0.000 description 2
230000007017 scission Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
210000004989 spleen cell Anatomy 0.000 description 2
210000004988 splenocyte Anatomy 0.000 description 2
238000003860 storage Methods 0.000 description 2
238000011285 therapeutic regimen Methods 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
FZZMTSNZRBFGGU-UHFFFAOYSA-N 2-chloro-7-fluoroquinazolin-4-amine Chemical compound FC1=CC=C2C(N)=NC(Cl)=NC2=C1 FZZMTSNZRBFGGU-UHFFFAOYSA-N 0.000 description 1
101150044182 8 gene Proteins 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
102100027211 Albumin Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
108020000946 Bacterial DNA Proteins 0.000 description 1
102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
108010029697 CD40 Ligand Proteins 0.000 description 1
102100032937 CD40 ligand Human genes 0.000 description 1
102000008203 CTLA-4 Antigen Human genes 0.000 description 1
108010021064 CTLA-4 Antigen Proteins 0.000 description 1
229940045513 CTLA4 antagonist Drugs 0.000 description 1
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000178270 Canarypox virus Species 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010055166 Chemokine CCL5 Proteins 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
240000006162 Chenopodium quinoa Species 0.000 description 1
235000015493 Chenopodium quinoa Nutrition 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
241000759568 Corixa Species 0.000 description 1
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
108010072220 Cyclophilin A Proteins 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108060003393 Granulin Proteins 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
241001316290 Gypsophila Species 0.000 description 1
102000006481 HIV Receptors Human genes 0.000 description 1
108010083930 HIV Receptors Proteins 0.000 description 1
108010078851 HIV Reverse Transcriptase Proteins 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 1
101710203526 Integrase Proteins 0.000 description 1
108090000174 Interleukin-10 Proteins 0.000 description 1
108090000176 Interleukin-13 Proteins 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
108010002616 Interleukin-5 Proteins 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
101710128836 Large T antigen Proteins 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101000713102 Mus musculus C-C motif chemokine 1 Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
102000005877 Peptide Initiation Factors Human genes 0.000 description 1
108010044843 Peptide Initiation Factors Proteins 0.000 description 1
108010013639 Peptidoglycan Proteins 0.000 description 1
102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
108010019653 Pwo polymerase Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
241000220010 Rhode Species 0.000 description 1
241000714474 Rous sarcoma virus Species 0.000 description 1
KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
239000002262 Schiff base Substances 0.000 description 1
102000003800 Selectins Human genes 0.000 description 1
108090000184 Selectins Proteins 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
101150057615 Syn gene Proteins 0.000 description 1
108700005078 Synthetic Genes Proteins 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
229920006355 Tefzel Polymers 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
102000008233 Toll-Like Receptor 4 Human genes 0.000 description 1
108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
102000002689 Toll-like receptor Human genes 0.000 description 1
108020000411 Toll-like receptor Proteins 0.000 description 1
102400001320 Transforming growth factor alpha Human genes 0.000 description 1
101800004564 Transforming growth factor alpha Proteins 0.000 description 1
108090000848 Ubiquitin Proteins 0.000 description 1
102000044159 Ubiquitin Human genes 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000006154 adenylylation Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
229920000180 alkyd Polymers 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
210000004507 artificial chromosome Anatomy 0.000 description 1
238000013475 authorization Methods 0.000 description 1
239000000022 bacteriostatic agent Substances 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000002210 biocatalytic effect Effects 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
229960003150 bupivacaine Drugs 0.000 description 1
229910052793 cadmium Inorganic materials 0.000 description 1
BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
210000000234 capsid Anatomy 0.000 description 1
125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
210000004970 cd4 cell Anatomy 0.000 description 1
230000034303 cell budding Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
108091092356 cellular DNA Proteins 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
210000003793 centrosome Anatomy 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical group OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
230000000139 costimulatory effect Effects 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000002716 delivery method Methods 0.000 description 1
230000017858 demethylation Effects 0.000 description 1
238000010520 demethylation reaction Methods 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
238000011161 development Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
108010027836 endotoxin receptor Proteins 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
229940011399 escin Drugs 0.000 description 1
229930186222 escin Natural products 0.000 description 1
QHSJIZLJUFMIFP-UHFFFAOYSA-N ethene;1,1,2,2-tetrafluoroethene Chemical compound C=C.FC(F)=C(F)F QHSJIZLJUFMIFP-UHFFFAOYSA-N 0.000 description 1
HASJWDPFBRPJNC-UHFFFAOYSA-N ethyl 4-[(4-ethoxycarbonylanilino)methylamino]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1NCNC1=CC=C(C(=O)OCC)C=C1 HASJWDPFBRPJNC-UHFFFAOYSA-N 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
239000003337 fertilizer Substances 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
108700014844 flt3 ligand Proteins 0.000 description 1
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
230000037433 frameshift Effects 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
238000012826 global research Methods 0.000 description 1
230000005802 health problem Effects 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
239000001307 helium Substances 0.000 description 1
229910052734 helium Inorganic materials 0.000 description 1
SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
150000002429 hydrazines Chemical class 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000015788 innate immune response Effects 0.000 description 1
108700027921 interferon tau Proteins 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
238000011068 loading method Methods 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
239000003607 modifier Substances 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
238000001823 molecular biology technique Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
239000000178 monomer Substances 0.000 description 1
150000004712 monophosphates Chemical class 0.000 description 1
238000000465 moulding Methods 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
229940100662 nasal drops Drugs 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
210000001331 nose Anatomy 0.000 description 1
230000025308 nuclear transport Effects 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
150000002923 oximes Chemical class 0.000 description 1
238000012536 packaging technology Methods 0.000 description 1
239000013618 particulate matter Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
150000004032 porphyrins Chemical class 0.000 description 1
229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
230000008569 process Effects 0.000 description 1
AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
239000003380 propellant Substances 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
239000012264 purified product Substances 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000036647 reaction Effects 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000003014 reinforcing effect Effects 0.000 description 1
229950010550 resiquimod Drugs 0.000 description 1
229910052707 ruthenium Inorganic materials 0.000 description 1
238000010206 sensitivity analysis Methods 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
239000002002 slurry Substances 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
229940031626 subunit vaccine Drugs 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000009182 swimming Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
229940021747 therapeutic vaccine Drugs 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
229940100611 topical cream Drugs 0.000 description 1
230000005758 transcription activity Effects 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000010474 transient expression Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
230000009452 underexpressoin Effects 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
108700026220 vif Genes Proteins 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000029302 virus maturation Effects 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
108700026215 vpr Genes Proteins 0.000 description 1
239000008215 water for injection Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Mycology (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Plant Pathology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

TW091121625A 2001-12-11 2002-09-20 Vaccines TWI329647B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB0129604A GB0129604D0 (en)	2001-12-11	2001-12-11	Novel compounds
GB0206462A GB0206462D0 (en)	2002-03-19	2002-03-19	Vaccines

Publications (1)

Publication Number	Publication Date
TWI329647B true TWI329647B (en)	2010-09-01

Family

ID=43927344

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW091121625A TWI329647B (en)	2001-12-11	2002-09-20	Vaccines

Country Status (6)

Country	Link
KR (1)	KR101067231B1 (de)
AT (1)	ATE506439T1 (de)
DE (1)	DE60239815D1 (de)
MY (1)	MY131949A (de)
TW (1)	TWI329647B (de)
ZA (1)	ZA200402189B (de)

2002
- 2002-09-18 DE DE60239815T patent/DE60239815D1/de not_active Expired - Lifetime
- 2002-09-18 KR KR1020047004128A patent/KR101067231B1/ko not_active Expired - Fee Related
- 2002-09-18 AT AT02798748T patent/ATE506439T1/de not_active IP Right Cessation
- 2002-09-20 MY MYPI20023515A patent/MY131949A/en unknown
- 2002-09-20 TW TW091121625A patent/TWI329647B/zh not_active IP Right Cessation
2004
- 2004-03-18 ZA ZA2004/02189A patent/ZA200402189B/en unknown

Also Published As

Publication number	Publication date
ATE506439T1 (de)	2011-05-15
MY131949A (en)	2007-09-28
DE60239815D1 (de)	2011-06-01
ZA200402189B (en)	2005-07-27
KR20040039387A (ko)	2004-05-10
HK1066830A1 (en)	2005-04-01
KR101067231B1 (ko)	2011-09-22

Legal Events

Date	Code	Title	Description
2013-06-01	MM4A	Annulment or lapse of patent due to non-payment of fees

Publication	Publication Date	Title
AU2002362368B2 (en)	2006-09-21	HIV-gag codon-optimised DNA vaccines
KR100571479B1 (ko)	2007-06-07	Hiv에 대한 폴리엔브백신으로서 재조합 백시니아벡터의 혼합물
EP0689551B1 (de)	2008-02-20	Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
AU2002362368A1 (en)	2003-06-05	HIV-gag codon-optimised DNA vaccines
US20070248679A1 (en)	2007-10-25	Vaccine
JP2012012416A (ja)	2012-01-19	Ｈｉｖワクチン処方物
HRP970092A2 (en)	1998-04-30	Synthetic hiv genes
US20070042977A1 (en)	2007-02-22	Vaccine
US20020197711A1 (en)	2002-12-26	Coxsackievirus B4 expression vectors and uses thereof
Baier et al.	1995	Immunogenic targeting of recombinant peptide vaccines to human antigen-presenting cells by chimeric anti-HLA-DR and anti-surface immunoglobulin D antibody Fab fragments in vitro
US20090169503A1 (en)	2009-07-02	Dna-based vaccination of retroviral-infected individuals undergoing treatment
TWI329647B (en)	2010-09-01	Vaccines
RU2312896C2 (ru)	2007-12-20	Последовательность нуклеиновой кислоты, кодирующая белок gag вич-1, способ получения указанной последовательности, вектор, содержащий ее, белок, кодируемый ею, фармацевтическая композиция и их применение для профилактики и/или лечения вич-инфекции и спида
ES2364466T3 (es)	2011-09-02	Vacunas de adn optimizadas por codón rt-nef-gaf para vih.
CN101255434A (zh)	2008-09-03	疫苗
HK1066830B (en)	2011-12-16	Hiv- rt-nef-gag codon optimised dna vaccines